Biohaven Pharma is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for neuroscience, immunology, and oncology. Using proprietary modular drug development platforms and strategic collaborations, it accelerates the creation of treatments for high‑unmet‑need conditions such as epilepsy, spinal muscular atrophy, and rare neurogenetic disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with neurological, immunological, and oncological diseases often have limited or no effective treatment options, leading to unmet medical needs and delayed therapeutic outcomes.
Solution
Biohaven Pharma addresses this gap by operating a biopharmaceutical platform that discovers, develops, and commercializes novel therapies across neuroscience, immunology, and oncology. The company leverages proprietary, modular drug development platforms that enable rapid generation of candidates targeting high‑unmet‑need indications. It augments internal research with licensed intellectual property from leading institutions and pharmaceutical partners to broaden its pipeline. Advanced digital tools and an agile operating model accelerate clinical development and enhance patient engagement. Biohaven’s portfolio includes late‑stage programs such as a Kv7 channel activator for epilepsy and a myostatin‑targeting fusion protein for spinal muscular atrophy and obesity, illustrating its focus on innovative mechanisms of action.
Target Audience
Primary customers are healthcare providers, neurologists, immunologists, oncologists, and patients seeking innovative treatments for diseases with limited therapeutic options.
Features
- Modular, proprietary drug development platforms that streamline candidate design and optimization
- Integrated digital technologies for trial execution, data analytics, and patient interaction
- Strategic collaborations and licensed IP from companies and academic institutions (e.g., Pfizer, AstraZeneca, Yale) to expand therapeutic reach
- Diverse pipeline spanning neuroscience (e.g., Kv7 activators, CGRP antagonists), immunology, and oncology with multiple candidates in Phase 1‑3
- Focus on high‑unmet‑need diseases such as epilepsy, SMA, obesity, and rare neurogenetic disorders
- In‑house expertise in rapid clinic execution and regulatory strategy to accelerate approvals